Kineta Inc.

09/28/2023 | Press release | Distributed by Public on 09/28/2023 07:33

Kineta Announces Participation at October Investor Conferences

SEATTLE, Sept. 28, 2023 - Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today its participation in the following upcoming investor conferences in October 2023.

JonesTrading 2023 Healthcare Summit
Format: Investor meetings
Location: Miami, FL
Date: October 9-11, 2023

BIO Investor Forum
Format: Corporate presentation and investor meetings
Location: San Francisco, CA
Date: Tuesday, October 17, 2023
Time: 1:15-2:00 P.M. Pacific Time

OPAL Group Family Office & Private Wealth Management Forum West 2023
Format: Corporate presentation and investor meetings
Location: Napa, CA
Date: Thursday, October 19, 2023
Time: 10:50-11:10 P.M. Pacific Time

About Kineta
Kineta (Nasdaq: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients' lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27. For more information on Kineta, please visit, and follow Kineta on Twitter, LinkedIn and Facebook.


Kineta, Inc.:
Jacques Bouchy
EVP Investor Relations & Business Development
+1 206-378-0400
[email protected]

Investor Relations:
John Mullaly
LifeSci Advisors, LLC
[email protected]

Source: Kineta, Inc.